Nuvation Bio Reports Q3 2026 Revenue of $45 Million Driven by IBTROZI Growth
Nuvation Bio (NUVB) reported third-quarter 2026 revenue of $45 million, fueled by strong performance from its product IBTROZI and significant milestone payments from international collaborations. Net U.S. IBTROZI product revenue reached $27.5 million, representing an 18% sequential increase despite a broader 15% decline in total new patient starts across the ROS1 TKI market. The company reported a net loss of $41.9 million ($0.12 per share), which is an improvement over the $55.8 million loss recorded in the same period last year. Nuvation Bio maintains a strong liquidity position with $663.4 million in cash and marketable securities, supported by a recent $287.5 million convertible debt offering. Clinical progress continues with positive efficacy metrics for both TRUST-I and safusidenib programs.
Tickers: $NUVB
Topics: Clinical Development Market Share Product Sales Revenue Growth